---
document_datetime: 2025-03-27 16:56:28
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/respreeza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: respreeza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5153675
conversion_datetime: 2025-12-23 03:53:33.080237
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Respreeza

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 26/03/2025                          |                                             | Annex II                         | To update Annex II of the Product Information to |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000245783                        | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z (IB) - To update Annex II of the Product Information to amend the due date of the submission of the final clinical study report \"A randomized, long-term, post- authorisation, efficacy study has been agreed to study the dose-relationship if the higher API levels achieved in the blood might influence the rate of lung density decline and whether that would support an increased dose of 120mg/kg the market authorisation holder (MAH) should conduct and submit the results of a randomized, long-term, efficacy study conducted according to an agreed protocol\" from 31 March 2025 to 31 Mar 2034. Furthermore, the Marketing Authorisation Holder has taken the opportunity to introduce minor editorial   |            |     | amend the due date of the submission of the final clinical study report \"A randomized, long-term, post-authorisation, efficacy study has been agreed to study the dose-relationship if the higher API levels achieved in the blood might influence the rate of lung density decline and whether that would support an increased dose of 120mg/kg the market authorisation holder (MAH) should conduct and submit the results of a randomized, long-term, efficacy study conducted according to an agreed protocol\" from 31 March 2025 to 31 Mar 2034.   |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000249049 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 07/03/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|